Contents hide 1 About Adagrasib 2 Non–Small Cell Lung Cancer 3 Colorectal Cancer 3.1 In a clinical trial, adagrasib was given with cetuximab 4 Dosage Modifications 4.1 Dosage reductions for adverse reactions 4.2 Nausea or vomiting 4.3 Diarrhea 4.4 QT interval prolongation 4.4.1 Corrected QT (QTc) absolute value >500 msec OR an increase >60 msec from baseline 4.4.2 Permanently discontinue 4.5 Hepatotoxicity 4.5.1 Grade 3 or 4 AST/ALT 4.5.2 Permanently discontinue 4.6 Interstitial lung disease (ILD) or pneumonitis (any grade) 4.7 Other adverse reactions 4.7.1 Grade 3 or 4 4.8 Renal impairment 4.9 Hepatic impairment 5 Dosing Considerations 5.1 Monitoring … Continue reading ADADX (Adagrasib)